AEGiS-SC: Price reduction in AZT urged by federal expert on AIDS San Francisco ChronicleImportant note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.
Click here to return to San Francisco Chronicle main menu
DonateNow


Price reduction in AZT urged by federal expert on AIDS

San Francisco Chronicle - Friday, August 25, 1989
Elaine Herscher, Chronicle Staff Writer


The manufacturer of the drug AZT, shown to be effective in delaying the onset of AIDS, should reduce the drug's prohibitive price, one of the top federal experts on the disease said yesterday.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, conducted a study released last week that showed that the drug AZT delays the start of AIDS in people infected with the HIV virus but who have no AIDS symptoms.

The study opened the door for 650,000 Americans who are infected but outwardly healthy to begin treatment with AZT, which costs $8,000 per person a year. "From a scientific standpoint, whether you have symptoms or not, you should be taking the drug," Fauci said at a conference on lesbian and gay health care in San Francisco. "We really need to have pressure on the drug company about getting the price down," he said. Burroughs Wellcome, the drug's manufacturer, maintains that the high cost resulted from AZT's research and development. The study showed that AZT delays the start of the disease in people infected by the virus who have no symptoms but whose count of T4 cells has fallen below 500 per cubic centimeter. In his keynote address, Fauci also noted a growing federal government backlash against money for AIDS research. In the past year, the AIDS research budget for Fauci's agency has risen 28.5 percent to $400 million while research financing for all other diseases has increased only 3.2 percent to $443 million.


Keywords: AIDS; COST; DRUGS; AZT; ANTHONY FAUCIKWDaids;cost;drugs;azt;anthonyfauci
890825
SC890809

Copyright © 1989 - San Francisco Chronicle Press. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the San Francisco Chronicle, Permissions Desk, 901 Mission Street, San Franciso, CA 94103. You may also send a fax to (415) 495-3843, or an email message to chronperm@sfgate.com.   http://www.sfgate.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .